Additional Products

Through its wholly-owned subsidiary, NX Development Corp. (“NXDC”), NX PharmaGen has also optioned rights to an additional potentially synergistic technology.

Gliolan®, is a fluorescence-guided resection imaging agent, which is marketed in the EU for malignant glioma cases and for which NXPG has obtained an option to license North American marketing rights from Photonamic Gmb&H (Germany).